 |
Welcome to |
|
BEAVERTON, Ore., March 3 /PRNewswire/ -- Epitope, Inc. (Nasdaq: EPTO) today announced that Edward V. Collom, Jr. has been named Vice President of Sales and Marketing, effective March 9, 1998. "We are delighted to have Ed join Epitope. His background and experience not only fit our existing product line, but also will be invaluable as we expand our patented technology platform into the drugs-of-abuse testing market," said John W. Morgan, president and chief executive officer. Epitope previously announced that the FDA had cleared use of the company's OraSure device with enzyme immunoassays manufactured by STC Technologies, Inc., to test for cocaine, methamphetamines and THC. "The drugs-of-abuse testing market represents a major new initiative for Epitope in expanding its patented technology platform and Ed's background will help us launch our sales efforts more quickly and effectively," Morgan stated. Mr. Collom was hired following a national search for an experienced sales and marketing executive. Prior to accepting his position with Epitope, Mr. Collom was with PharmChem Laboratories, Menlo Park, California, where he had responsibility for the sales and marketing of forensic drug testing services, and drugs-of-abuse and on-site drug screening devices. Mr. Collom has also worked with Boehringer Mannheim, Specialty Laboratories, Johnson & Johnson- Ortho Diagnostics and E.I. Dupont, where he gained experience with HIV, hepatitis and Western blot products. Epitope, Inc. is an Oregon-based corporation that develops and markets medical diagnostic products. Its principal products, including the OraSure oral specimen collection device, focus on the use of oral fluid to detect HIV infection and other conditions, and are marketed primarily in the life insurance and public health sectors. Source: EPITOPE Inc. Content of this page is copyright and reprinted here for educational and historical information. |
||
